News for Healthier Living

Evergreen Theragnostics Opens CCK2-VIEW, a Phase II Small Cell Lung Cancer Clinical Trial, in the European Union

Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, focused on providing additional treatment options for cancer patients, is pleased to announce opening of its trial of 68Ga-EVG321 for patients with small cell lung cancer in the European Union, after receiving approval by the European Medicines Agency (EMA) to start recruitment (EUCT ID # 2024-514584-25-00).

October 18, 2024


October 19 2024

October 18 2024

October 17 2024

October 16 2024

October 15 2024

October 14 2024

October 13 2024

October 12 2024

October 11 2024

October 10 2024

October 9 2024

October 8 2024

October 7 2024

October 6 2024

October 5 2024